glp 1 with kidney disease Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic through dampening the receptor for advanced glycation end products–induced inflammation Glucagon-Like Peptide-1 Receptor Agonist Use

Chem Rev

In clinical trials for Ozempic (subcutaneous semaglutide for diabetes), diarrhea occurred in approximately 8.5% of patients receiving 0.5 mg and 8.3% of patients receiving 1 mg doses, compared to 4.3% in placebo groups

G #283 [Video]

The paper noted that continued poor intake of such essential micronutrients could lead to detrimental long-term health outcomes, including impacts on cardiovascular health and bone density

10.1007/s00198-018-4649-8 Summary Keywords glucagon-like peptide-1, diabetes mellitus, glucagon-like peptide 1 receptor agonists, osteoporosis, bone resorption Citation Xie B, Chen S, Xu Y, Han W, Hu R, Chen M, Zhang Y and Ding S (2021) The Impact of Glucagon-Like Peptide 1 Receptor Agonists on Bone Metabolism and Its Possible Mechanisms in Osteoporosis Treatment

Jacobson DA, Wicksteed BL, Philipson LH